Product Information
SELEGILINE HCL 5 MG TABLET is a generic product labeled by i3 Pharmaceuticals, LLC, priced at $0.7657 per EA under NDC 72319000602. Its NADAC has been published 233 times since Apr 20, 2022.
FDA first approved this application on Apr 1, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
i3 Pharmaceuticals, LLCNDC
72319000602
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SELEGILINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA074672FDA Approved
4/1/1997
TE Code
AB
On Market Since
12/15/2021
Pharmacological Classes
Price Statistics
The NADAC for SELEGILINE HCL 5 MG TABLET has been published 233 times since Apr 20, 2022, and over the history we have for it it has declined 24.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7657 per EA |
|---|---|
| All-time high | $1.0975 (Aug 10, 2022) |
| All-time low | $0.6101 (Jul 17, 2024) |
| 52-week high | $0.8231 |
| 52-week low | $0.6895 |
| Median price | $0.8121 |
| Average price | $0.8255 |
| Largest weekly change | +33.5% (May 17, 2023) |
| Weeks tracked | 233 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
i3 Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Selegiline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Monoamine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SELEGILINE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SELEGILINE HCL 5 MG TABLET, manufactured by i3 Pharmaceuticals, LLC, is $0.7657 per EA (NDC 72319000602), effective Sep 30, 2026.
How has the price of SELEGILINE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SELEGILINE HCL 5 MG TABLET has declined 24.1%. It has been tracked across 233 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for SELEGILINE HCL 5 MG TABLET?
Since Apr 20, 2022, the NADAC for SELEGILINE HCL 5 MG TABLET has ranged from a low of $0.6101 (Jul 17, 2024) to a high of $1.0975 (Aug 10, 2022), with a median of $0.8121 per EA.
Are there cheaper alternatives to SELEGILINE HCL 5 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SELEGILINE HCL 5 MG TABLET, is $0.6101 per EA — about 20% below SELEGILINE HCL 5 MG TABLET.
Who manufactures SELEGILINE HCL 5 MG TABLET?
SELEGILINE HCL 5 MG TABLET (NDC 72319000602) is labeled by i3 Pharmaceuticals, LLC, and CMS classifies it as a generic product.